Ultima Genomics

What Ultima Genomics does

Ultima Genomics is a venture-backed developer of high-throughput, low-cost DNA sequencing instruments and consumables, founded in 2016 by Gilad Almogy (formerly of Applied Materials) and headquartered in the San Francisco Bay Area. The company emerged from stealth in May 2022 alongside a $600M financing round and has subsequently raised cumulative capital exceeding $700M from a tier-1 investor syndicate led by Andreessen Horowitz and including Khosla Ventures, General Atlantic, Lightspeed, Playground Global, D1 Capital, Founders Fund, and aMoon. Its installed base spans research institutions, clinical laboratories, consumer genomics services, and pharmaceutical R&D programs across North America, EMEA, and APAC, with distribution supported by a global Certified Service Provider network of 12+ providers including Broad Clinical Labs, IQVIA Laboratories, Macrogen, Novogene, and Gene By Gene.

The company's core technology is a sequencing-by-synthesis architecture built on an open 200mm silicon wafer substrate (replacing conventional glass flow cells) with flow-based chemistry and rotational imaging. Its product family comprises the UG 100 and the 2026-launched UG200 Series (single-wafer UG200 and dual-wafer UG200 Ultra), paired with Solaris / Solaris 2.0 amplification and library-prep chemistry and the proprietary ppmSeq (paired plus-minus sequencing) error-correction method that achieves part-per-million SNV accuracy by sequencing both strands of each template. List pricing for UG 200-series instruments is reported at $850K–$1.25M, with per-genome consumable pricing as low as $80 at 30x coverage and throughput capacity exceeding 60,000 whole genomes per year on a single UG 200 Ultra. The integrated software stack includes on-board secondary analysis plus UG-adapted DeepVariant, Sentieon DNAscope, and GATK pipelines, with open-source WDL workflows available on AWS HealthOmics.

Revenue is generated through three streams: capital sales of sequencing instruments, recurring consumables (single-use wafers, reagents, adapters, and Solaris library-prep kits), and sequencing-as-a-service via the in-house Technology Access Program. The model is hybrid — direct enterprise sales for instruments and TAP, complemented by the CSP channel that delivers Ultima sequencing capacity to end customers without instrument purchase. Focus application areas include population-scale germline whole-genome sequencing, oncology and minimal-residual-disease detection, single-cell and spatial transcriptomics, proteomics, and methylation profiling, with a large integration ecosystem spanning 10x Genomics, Olink, Parse Biosciences, BD, Scale Bio, BioSkryb, IDT, Twist, NEB, Watchmaker, Fabric Genomics, NVIDIA, AWS, Sentieon, GATK, Sapio Sciences, and Hamilton.

Name

Ultima Genomics

Legal name

Ultima Genomics, Inc.

Website

https://ultimagenomics.com

Company type

Private

Founded year

2016

Operating status

Operating

Headcount range

251–500 employees

Short description

Ultima Genomics develops high-throughput, low-cost DNA sequencing instruments (UG 100 and UG200 Series) based on a silicon-wafer substrate and paired plus-minus (ppmSeq) chemistry, serving research institutions, clinical labs, population-genomics consortia, and consumer-genomics service providers via direct sales and a global Certified Service Provider network.

Ownership category

akta.pro rank

Product category

DNA Sequencing Instruments

NAICS

Medical Laboratories (621511), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Laboratory Analytical Instruments (3826), Services-Medical Laboratories (8071)

akta.pro primary industry

Molecular Biology & Genomics Instruments (PCR/qPCR, Sequencing, Microarrays) (HLAGAIAF)

Keywords

• DNA sequencing platform
• Next generation sequencing
• Whole genome sequencing
• Library prep workflows
• Sequencing reagents

Headquarters

HQ city

Newark

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Supply Chain, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Instrument hardware sales: One-time capital sales of UG 100, UG 200, and UG 200 Ultra sequencing systems to research and clinical laboratories (priced from ~$850,000 to ~$1,250,000 per instrument).
2. Consumables (wafers, reagents, adapters, library prep kits): Recurring revenue from single-use wafer consumables, flow reagents, sequencing adapters, and Solaris / Solaris 2.0 library preparation kits that attach to the installed instrument base.
3. Technology Access Program (sequencing services): Fee-for-service sequencing operated by Ultima Genomics itself; customers submit samples and receive data, providing an alternative path to access without instrument purchase.

Pricing tiers

Go-to-market motion4 records

Distribution channels4 records

Marketing channels8 records

Core offering

Ultima Genomics develops and sells high-throughput DNA sequencing instruments (UG 100, UG200, UG200 Ultra) built on a proprietary open 200mm silicon wafer substrate and flow-based sequencing-by-synthesis chemistry, paired with recurring consumables (wafers, reagents, Solaris/Solaris 2.0 library prep, ppmSeq paired plus-minus chemistry) and on-board analysis software. The company also operates a Technology Access Program providing sequencing-as-a-service and a global Certified Service Provider network for sample-to-data delivery.

Differentiator

Problem solved

Functional benefit

Brands

• UG 100 Sequencing Platform: High-throughput, low-cost sequencing platform featuring an open 200mm silicon wafer substrate and mostly natural sequencing-by-synthesis flow chemistry.
• UG200 Series
• ppmSeq
• Solaris 2.0

Products and services

• UG 100 Sequencing Platform First-generation high-throughput DNA sequencing instrument built on an open 200mm silicon wafer substrate with rotational imaging and mostly natural flow-based sequencing-by-synthesis chemistry. With Solaris workflows the platform delivers 10-12 billion reads per wafer at $0.24 per million reads, supporting up to 30,000+ whole genomes per year for research and clinical laboratories.
• UG200 Series (UG200 and UG200 Ultra) Second-generation sequencing instrument platform launched in February 2026 with two configurations (UG200 single-wafer and UG200 Ultra dual-wafer) delivering doubled output, halved runtime, and halved footprint versus the UG 100. Uses rapid isothermal amplification for seamless lab automation integration; UG200 Ultra sequences more than 60,000 whole genomes per year at 30x coverage and runs up to 60 automated runs per week with single-shift operation.
• ppmSeq (paired plus-minus sequencing) Paired plus-minus sequencing chemistry that achieves one part-per-million or better SNV detection accuracy by sequencing both strands of a captured DNA molecule and removing disagreement caused by sample errors. Enables part-per-million rare variant detection in liquid biopsy and minimal residual disease (MRD) applications and supports 30x whole-genome sequencing from 2ng of cfDNA.
• Solaris Free and Solaris Flex library prep workflows Library preparation workflows for the UG 100 sequencing platform. Solaris Free provides PCR-free library prep compatible with leading third-party library prep kits (e.g., xGen PCR-Free Adapters for Ultima Genomics from IDT and UG ppmSeq Adapters), while Solaris Flex adapts existing third-party libraries through a simple indexing PCR step.
• Solaris 2.0 amplification chemistry and library prep workflows Next-generation amplification chemistry and library prep workflows for the UG200 Series, featuring Solaris 2.0 Free (PCR-free) and Solaris 2.0 Flex (indexing PCR) workflows with improved GC coverage uniformity and variant calling accuracy. Solaris 2.0 Max provides up to 20 billion reads per wafer with a 7-hour amplification workflow requiring only 10 minutes of hands-on time.
• Analysis & Bioinformatics Solutions Integrated software suite with on-board UG 100 Server performing primary and secondary analysis without impacting sequencing throughput. Includes the Ultima Aligner optimized for flow chemistry, on-board demultiplexing, UMI-aware deduplication, alt-aware alignment, and compatibility with UG-adapted DeepVariant, Sentieon DNAscope, GATK UG flow mode, and AWS HealthOmics cloud workflows.
• Certified Service Provider (CSP) Network Global network of rigorously vetted service providers offering Ultima sequencing services to end customers. Includes Broad Clinical Labs, Gene By Gene, Inocras, IQVIA Laboratories, Macrogen, McGill Genome Centre, New York Genome Center, Novogene Americas, Ontario Institute for Cancer Research, Psomagen, University of Michigan Advanced Genomics Core, and University of Minnesota Genomics Center.
• Technology Access Program (TAP) In-house sequencing-as-a-service program that provides access to Ultima's applications lab and high-capacity fleet of UG 100 sequencers, including consultation, sample submission, sequencing, QC, bioinformatics analysis, and ongoing support from consultation through data interpretation.

Quantifiable outcome

• More than 60,000 30x whole genomes per year on a single UG 200 Ultra
• +3 more outcomes

Named customers18 records

Segments4 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration19 records

AI capability6 records

Feature5 records

Partnerships

34 partnerships are on record, tiered flagship and core.

• Hartwig Medical FoundationflagshipStrategic or Co-development Partner · 1 June 2026Strategic collaboration on population-scale whole-genome oncology sequencing. Co-develops workflows around ppmSeq and the UG 200 platform to advance cancer genomics research.
• MacrogencoreGTM or Marketing Partner · 1 April 2026Co-hosted AI genome analysis symposium to expand Ultima adoption across APAC. Macrogen also acts as a Certified Service Provider.
• Basecamp ResearchflagshipStrategic or Co-development Partner · 1 March 2026Joint Trillion Gene Atlas initiative covering 31 countries; Ultima provides sequencing capacity and ppmSeq accuracy while Basecamp contributes biodiversity and discovery data assets.
• Hamilton CompanycoreTechnology or Integration · 1 February 2026Automation partnership integrating Hamilton liquid-handling robotics with Ultima's sequencing workflows to enable high-throughput laboratory automation.
• MyHeritageflagshipStrategic or Co-development Partner · 1 October 2025Strategic partnership to deliver a consumer whole-genome sequencing testing product powered by Ultima's technology.
• Gene By GeneflagshipStrategic or Co-development Partner · 1 October 2025Whole-genome sequencing service partnership; Gene By Gene operates 100,000-sample-per-month capacity using Ultima instruments and is also a Certified Service Provider.
• Sapio SciencescoreTechnology or Integration · 1 September 2025Lab informatics partnership integrating Sapio's lab informatics platform with Ultima sequencing workflows to streamline sample-to-data pipelines.
• Chan Zuckerberg InitiativecoreStrategic or Co-development Partner · 1 January 2024Partner on the Billion Cells Project leveraging Ultima sequencing for large-scale single-cell research.
• 10x GenomicsflagshipTechnology or Integration · 1 January 2024Technology integration combining 10x single-cell and spatial transcriptomics with Ultima sequencing for large-scale single-cell studies.
• OlinkcoreTechnology or Integration · 1 January 2024Proteomics integration combining Olink's proteomic assays with Ultima sequencing workflows.
• Parse BiosciencescoreTechnology or Integration · 1 January 2024Single-cell integration combining Parse's single-cell chemistry with Ultima sequencing.
• Scale BiosciencescoreTechnology or Integration · 1 January 2024Single-cell technology integration with Ultima sequencing.
• Integrated DNA Technologies (IDT)coreTechnology or Integration · 1 January 2024Library prep integration with IDT's reagents for use on Ultima sequencers.
• Twist BiosciencecoreTechnology or Integration · 1 January 2024Library prep integration using Twist's synthetic biology reagents on the Ultima platform.
• New England Biolabs (NEB)coreTechnology or Integration · 1 January 2024Library prep integration with NEB reagents for Ultima sequencing workflows.
• Watchmaker GenomicscoreTechnology or Integration · 1 January 2024Library prep integration with Watchmaker's enzymes for use on Ultima sequencers.
• Fabric GenomicscoreTechnology or Integration · 1 January 2024Analysis integration providing tertiary / clinical interpretation for Ultima sequencing data.
• Amazon Web Services (AWS)flagshipTechnology or Integration · 1 January 2024Cloud infrastructure integration enabling Ultima customers to run genomic analysis workflows on AWS.
• NVIDIAflagshipTechnology or Integration · 1 January 2024Infrastructure partnership leveraging NVIDIA accelerated computing for secondary analysis of Ultima sequencing data.
• SentieoncoreTechnology or Integration · 1 January 2024Analysis integration using Sentieon's variant calling pipelines optimized for Ultima data.
• GATKcoreTechnology or Integration · 1 January 2024Analysis integration with the Broad's GATK best-practices pipelines for Ultima sequencing data.
• Becton Dickinson (BD)coreTechnology or Integration · 1 January 2024Single-cell technology integration combining BD's single-cell portfolio with Ultima sequencing.
• Broad Clinical LabscoreChannel Partner/ Reseller/ DistributorCertified Service Provider based in Boston, MA offering Ultima sequencing services to its clinical and research customers.
• Gene By GeneflagshipChannel Partner/ Reseller/ DistributorCertified Service Provider in Houston, TX operating the largest commercial deployment of Ultima sequencers with capacity for 100,000 whole genomes per month.
• InocrascoreChannel Partner/ Reseller/ DistributorCertified Service Provider in San Diego, CA offering Ultima-powered clinical genomics, including MRD and cancer applications.
• IQVIA LaboratoriesflagshipChannel Partner/ Reseller/ DistributorCertified Service Provider in Durham, NC leveraging Ultima sequencing for large-scale clinical and pharmaceutical genomics programs.
• MacrogenflagshipChannel Partner/ Reseller/ DistributorCertified Service Provider based in Seoul, South Korea offering Ultima sequencing capacity across APAC.
• McGill Genome CentrecoreChannel Partner/ Reseller/ DistributorCertified Service Provider based in Montreal, Canada offering Ultima sequencing to academic researchers.
• New York Genome CenterflagshipChannel Partner/ Reseller/ DistributorCertified Service Provider in New York, NY offering Ultima sequencing to the NYC research community.
• Novogene AmericasflagshipChannel Partner/ Reseller/ DistributorCertified Service Provider in Beaverton, OR offering Ultima sequencing across North America.
• Ontario Institute for Cancer ResearchcoreChannel Partner/ Reseller/ DistributorCertified Service Provider in Ontario, Canada using Ultima sequencing for oncology research programs.
• PsomagencoreChannel Partner/ Reseller/ DistributorCertified Service Provider in Rockville, MD offering Ultima sequencing to clinical and research customers.
• University of Michigan Advanced Genomics CorecoreChannel Partner/ Reseller/ DistributorCertified Service Provider running Ultima sequencing for University of Michigan researchers and external customers.
• University of Minnesota Genomics CentercoreChannel Partner/ Reseller/ DistributorCertified Service Provider offering Ultima sequencing to University of Minnesota researchers and external customers.

Scale indicators7 records

Recent moves7 records

Expansion highlights7 records

Broad incumbents

• Illumina: Dominant incumbent in short-read next-generation sequencing with an estimated majority share of installed sequencers worldwide. Ultima directly competes against Illumina's NovaSeq, NextSeq, and iSeq platforms on throughput and per-genome cost, while targeting Illumina's installed base through cost disruption.
• NeoGenomics: Clinical oncology laboratory services company with a large installed clinical footprint in oncology testing. NeoGenomics is a partnership customer for Ultima but also a competitor/alternative for clinical WGS and MRD testing in oncology, especially where labs default to incumbent platforms.

Direct peers

• Pacific Biosciences: Long-read sequencing platform (Revio, Sequel) competing for population-scale and clinical genomics workloads alongside Ultima. Pacific Biosciences shares much of Ultima's enterprise sales motion and several of Ultima's senior leaders (e.g., Chris Seipert, Lara Toerien, Jason Kang) come from PacBio, and they are co-collaborators on Basecamp Research's Trillion Gene Atlas.
• Oxford Nanopore Technologies: Nanopore-based long-read sequencing provider competing across research, clinical, and applied genomics markets. Both companies pursue population-scale sequencing economics and clinical oncology applications, and both compete for the same academic and translational research budgets.
• MGI Tech (BGI Group): Low-cost NGS and DNA nanoball sequencing platforms (DNBSEQ) positioned as the most direct cost-disruptive competitor to Ultima, particularly in APAC. MGI's aggressive pricing mirrors Ultima's per-genome economics, making it the primary head-to-head competitor for population-scale and clinical WGS contracts.
• Element Biosciences: Emerging NGS platform (AVITI) targeting low-cost, high-accuracy short-read sequencing with a novel avidity-based chemistry. Element is the closest US-based emerging competitor to Ultima on cost-per-sample and accuracy, competing for the same research and clinical early-adopter accounts.
• Complete Genomics: Sequencing instruments and services (now under MGI/BGI) historically positioned for low-cost human whole-genome sequencing. Comparable to Ultima in technology philosophy and population-scale WGS ambitions; BGI integration increases scale and competitive overlap.

Emerging players

• Singular Genomics: Developer of the G4 benchtop sequencing platform targeting multiomic applications including single-cell, spatial, and targeted sequencing. Singular competes with Ultima at the lower-throughput / mid-size lab end of the market rather than Ultima's population-scale footprint.
• GenapSys: Early-stage low-cost sequencing platform using electrical detection. Florian Oberstrass (SVP Technology Development at Ultima) previously led R&D at GenapSys, and both companies target decentralized, low-cost sequencing economics — GenapSys primarily at lower throughput than Ultima's UG100/UG200.
• 10x Genomics: Single-cell and spatial biology platform with validated integration onto the UG 100 sequencing platform. 10x is both an Ultima technology partner and a comparable company to the extent that end-customer sequencing decisions may favor 10x-linked workflows on incumbent Illumina versus Ultima.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/ultimagenomics
• GitHubgithub.com/Ultimagen
• LinkedInlinkedin.com/company/ultimagenomics

Revenue estimate

Valuation estimate

Number of profiles

Profiles18 records

Funding overview

Funding rounds2 records

Investors8 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Ultima Genomics